230 related articles for article (PubMed ID: 34668652)
1. Copy number variation analysis of m
Wang X; Yu J; Chen J; Hou Y; Du Z; Huang H; Tang S; Han Y; Ding C; Xue Z
Cancer Med; 2021 Nov; 10(21):7804-7815. PubMed ID: 34668652
[TBL] [Abstract][Full Text] [Related]
2. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
3. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence.
Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M
Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881
[TBL] [Abstract][Full Text] [Related]
4. Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancer.
Zhang Z; Yu Y; Zhang P; Ma G; Zhang M; Liang Y; Jiao W; Niu H
BMC Cancer; 2021 Apr; 21(1):458. PubMed ID: 33894748
[TBL] [Abstract][Full Text] [Related]
5. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.
Lyu Q; Lin A; Cao M; Xu A; Luo P; Zhang J
Cancer Control; 2020; 27(1):1073274820976665. PubMed ID: 33356494
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Analysis Identified ETV7 as a Potential Prognostic Biomarker in Bladder Cancer.
Li H; Zhang Y; Zheng S
Biomed Res Int; 2021; 2021():8530186. PubMed ID: 34926692
[TBL] [Abstract][Full Text] [Related]
7. Integrative analysis of prognostic long non-coding RNAs with copy number variation in bladder cancer.
Zhong W; Wang D; Yao B; Chen X; Wang Z; Qu H; Ma B; Ye L; Qiu J
J Zhejiang Univ Sci B; 2021 Aug; 22(8):664-681. PubMed ID: 34414701
[TBL] [Abstract][Full Text] [Related]
8. Gene Alterations of N6-Methyladenosine (m
Zhang Q; Cai Y; Kurbatov V; Khan SA; Lu L; Zhang Y; Johnson CH
Biomed Res Int; 2020; 2020():8826456. PubMed ID: 33415160
[TBL] [Abstract][Full Text] [Related]
9. Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer.
Qu G; Liu Z; Yang G; Xu Y; Xiang M; Tang C
Aging (Albany NY); 2021 Apr; 13(8):12099-12112. PubMed ID: 33888644
[TBL] [Abstract][Full Text] [Related]
10. Identification of METTL3 as an Adverse Prognostic Biomarker in Hepatocellular Carcinoma.
Liu GM; Zeng HD; Zhang CY; Xu JW
Dig Dis Sci; 2021 Apr; 66(4):1110-1126. PubMed ID: 32333311
[TBL] [Abstract][Full Text] [Related]
11. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of m
Guimarães-Teixeira C; Lobo J; Miranda-Gonçalves V; Barros-Silva D; Martins-Lima C; Monteiro-Reis S; Sequeira JP; Carneiro I; Correia MP; Henrique R; Jerónimo C
Mol Oncol; 2022 May; 16(9):1841-1856. PubMed ID: 35048498
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
14. The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas.
Ball MW; Gorin MA; Drake CG; Hammers HJ; Allaf ME
Eur Urol Focus; 2017 Dec; 3(6):584-589. PubMed ID: 28753846
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.
Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P
Front Immunol; 2023; 14():955949. PubMed ID: 37006317
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
17. A Three Protein-Coding Gene Prognostic Model Predicts Overall Survival in Bladder Cancer Patients.
Ning XH; Qi YY; Wang FX; Li SC; Jia ZK; Yang JJ
Biomed Res Int; 2020; 2020():7272960. PubMed ID: 33150179
[TBL] [Abstract][Full Text] [Related]
18. A new m6A methylation-related gene signature for prognostic value in patient with urothelial carcinoma of the bladder.
Zheng B; Wang J; Zhao G; Chen X; Yao Z; Niu Z; He W
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33779704
[TBL] [Abstract][Full Text] [Related]
19. Multiomics analysis identifies key genes and pathways related to N6-methyladenosine RNA modification in ovarian cancer.
Xu H; Li X; Wang S; Li F; Gao J; Yan L; Zhu L
Epigenomics; 2021 Sep; 13(17):1359-1383. PubMed ID: 34550011
[TBL] [Abstract][Full Text] [Related]
20. RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update.
He RQ; Huang ZG; Li TY; Wei YP; Chen G; Lin XG; Wang QY
Cell Physiol Biochem; 2018; 50(4):1474-1495. PubMed ID: 30359990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
